Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing
Ajinomoto OmniChem, an innovative provider of small molecule API, contract development and manufacturing services, today announced the successful completion of a commercial scale manufacturing campaign that involved adapting a traditional multi-step batch process into a continuous flow chemistry platform. Continuous flow manufacturing has several advantages over batch production including reduction of overall processing time, increased reaction selectivity, better product quality, saving on temporary storage costs, better control of the entire production process, and safer reactions at high temperatures & pressures when handling hazardous materials. The mobile installation of the continuous flow platform was designed and implemented in OmniChem’s pilot plan facility based in Wetteren, Belgium.
Dr. Eric De Vos, Business Unit and R&D Director of Pharmaceutical Fine Chemicals states: “We have been very eager to implement our continuous flow design and our teams have gained significant knowledge around this platform which will facilitate rapid changeovers and modifications for future client programs. Adopting continuous flow technology is instrumental to OmniChem’s expansion strategy and complements other service offerings including wiped film evaporation, build-out of additional suites for highly potent API and sensitive chemistry, oligopeptide and oligonucleotide manufacturing, micronization, and preparative HPLC.”
The continuous flow capability enables R&D and scale up to 100kg commercial levels and its modular construction allows for easy adaptation to other manufacturing processes. Building out this continuous flow platform is supported by the multi-year grant awards OmniChem received from the Belgian government to expand its processing windows and develop new types of reactors for rapid and selective chemical conversions in collaboration with technology providers.
This article has been republished from materials provided by OmniChem. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018